Several tumor-intrinsic determinants of resistance have been identified, including CD20 loss driven by <i>MS4A1</i> mutations, alternative splicing, and gene deletion, as well as genomic reprogramming involving <i>TP53</i>, <i>MYC</i>, and <i>NOTCH1</i> alterations. Here, TP53 is linked to neoplasm.